Oscar Health — InsurTech Growth Story in a Post-COVID World

Oscar Health, Inc. is a technology-driven health insurance company founded in 2012 and headquartered in New York City. The company operates primarily in the individual and small group health insurance markets, offering plans through the ACA exchanges across multiple states. Oscar Health generates revenue primarily through insurance premiums, supplemented by administrative services fees from its technology platform partnerships.

The company's business model centers on its proprietary technology platform, which includes a consumer-facing mobile application for claims management, telemedicine services, and personalized care coordination. With a focus on value-based care arrangements, Oscar Health partners with provider networks to manage healthcare costs effectively. The company serves approximately 1.3 million members across its markets, with a significant presence in Texas, New York, California, and Florida. Oscar Health also operates Oscar+, its co-branded product with Cigna for small businesses, expanding its total addressable market.

• Near-Term Growth Drivers: The company is positioned to benefit from the continued expansion of ACA enrollment, which has reached record levels in recent years. Oscar Health's geographic expansion into new states and counties, coupled with its participation in the enhanced subsidy environment through 2025, supports membership growth of 15% in the current year. Additionally, the company's Medicare Advantage (MA) pilot programs in select markets provide a new growth vector with higher revenue per member.
• Medium-Term Opportunities: Oscar Health's technology platform presents significant monetization opportunities beyond its core insurance business. The company's "Oscar for Business" segment, offering administrative services to self-insured employers, represents a scalable revenue stream with higher margins. Furthermore, partnerships with health systems and provider groups for value-based care coordination could drive additional fee-based income. Management targets a long-term operating margin of 5-7%, implying substantial earnings growth from current levels as the business scales.

The financial trajectory reflects Oscar Health's successful transition from growth-at-all-costs to disciplined profitability. Revenue growth has moderated to approximately 12-15% annually as the company prioritizes underwriting quality over membership expansion. The improvement in gross margins stems from better risk adjustment outcomes and favorable MLR trends, driven by the company's care management programs. Operating leverage is becoming evident as fixed technology costs are spread across a larger membership base, with management guiding toward sustained profitability from fiscal year 2025 onwards.

The U.S. health insurance market represents a substantial opportunity, with total industry premiums exceeding $1.2 trillion annually. Within the ACA individual market specifically, enrollment has stabilized at approximately 20 million lives, with Oscar Health holding roughly a 6-7% market share. The competitive landscape includes both traditional insurers and InsurTech challengers:

Oscar Health's competitive positioning relies on its technology differentiation and member experience, which has resulted in industry-leading Net Promoter Scores (NPS) among ACA insurers. However, the company faces intense price competition from larger players with deeper pockets, particularly UnitedHealth and Centene, who can leverage scale advantages in provider negotiations. The InsurTech space has seen consolidation and shakeouts, with several former competitors exiting the market due to underwriting losses, which has paradoxically strengthened Oscar Health's position as one of the few profitable tech-enabled carriers.

From a discounted cash flow (DCF) perspective, Oscar Health's valuation hinges on its ability to sustain growth while expanding margins. Assuming a 10% discount rate, 12% revenue growth over the next five years, and a terminal operating margin of 6%, the DCF yields an intrinsic value of approximately $38 per share. This implies the market is pricing in a successful execution of the company's growth strategy but with some margin of safety.

The comparable-company analysis reveals that Oscar Health trades at a premium to traditional insurers on most metrics, reflecting its growth profile and technology narrative. However, the P/E multiple of 56.5x on 2026 estimates appears stretched versus peers, suggesting the market is capitalizing future earnings growth. The EV/Revenue multiple of 1.3x sits between pure-play InsurTechs and established carriers, implying a balanced valuation that rewards execution but penalizes underperformance.

• Regulatory Risk: Changes to ACA subsidies, Medicaid expansion rules, or essential health benefits requirements could significantly impact membership and profitability. The expiration of enhanced subsidies after 2025 represents a specific near-term risk, potentially reducing enrollment by 10-15%.
• Underwriting Risk: Adverse claims experience, particularly from COVID-19 related pent-up demand or unexpected utilization spikes, could deteriorate the MLR and force premium increases that reduce competitiveness. The company's relatively small risk pool amplifies the impact of any single catastrophic claim event.
• Competitive Pressure: Larger insurers with superior scale and capital resources could engage in aggressive pricing strategies in Oscar Health's key markets, compressing margins or forcing the company to sacrifice growth. Recent market exits by weaker InsurTechs have reduced competition, but this dynamic could reverse with new entrants.
• Technology Dependency: As a technology-first company, Oscar Health faces execution risk in its platform development. Cybersecurity breaches, system outages, or failure to innovate could undermine the company's competitive advantage and damage its brand reputation with members.
• Execution Risk: The company's expansion into new markets and product lines carries inherent execution risks, including regulatory approval delays, provider network challenges, or mispricing in unfamiliar geographies. Management's relatively limited experience in Medicare Advantage could lead to costly missteps in this new vertical.